Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022
May 03, 2022 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
April 27, 2022 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
April 04, 2022 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
March 22, 2022 08:00 ET
|
Aligos Therapeutics
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including...
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
March 10, 2022 16:05 ET
|
Aligos Therapeutics
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA...
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
March 02, 2022 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 03, 2022 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
January 26, 2022 08:00 ET
|
Aligos Therapeutics
Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7...
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH
January 11, 2022 09:12 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133
January 06, 2022 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...